Celldex Therapeutics Inc. (CLDX) Company Profile & Statistics

Celldex Therapeutics Inc.
CLDX
(Nasdaq - US)
Open
23.30
-0.25 (-1.06%)
in:usd•As of: Nov 18, 2024 12:23 UTC -5
Open
23.76
High
23.76
Low
23.03

About Celldex Therapeutics Inc.

CEO

Anthony S. Marucci

Headquarters

53 frontage road,suite 220

hampton, nj 08827, united states

Auditor

PricewaterhouseCoopers LLP

Employees

160

Share Holders

133

Website

www.celldex.com

Industry

biotechnology

Sector

health technology

Company Overview

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Celldex Therapeutics Inc. Statistics

Valuation Measures

Market Capitalization ²	1.55B
Enterprise Value	1.51B
Enterprise Value/EBITDA (ttm)	-7.63
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.99
Price to Sales (ttm)	156.60
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-1419.03%
Profit Margin (ttm)	-6208.48%
Return on Equity (ttm)	-19.75%
Return on Invested Capital (ttm)	-23.77%
Return on Assets (ttm)	-18.86%

Income Statement

Revenue (ttm)	9.98M
Revenue Per Share (ttm)	0.15
Gross Profit (ttm)	9.98M
EBITDA (ttm)³	-198.13M
Net Income Avi to Common (ttm)	-154.08M
Diluted EPS (ttm)	-2.57

Share Statistics

Beta (5Y Monthly)	1.60
52-Week Change	-14.29%
S&P500 52-Week Change	29.59%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	66.34M
Dividend Yield	0.00%
Float ⁴	63.82M
% Held by Insiders	3.80%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	756.00M
Total Cash Per Share (mrq)	11.40
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	24.27%
Quick Ratio (mrq)	24.27%
Book Value Per Share (mrq)	11.85

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.89
Free Cash Flow (ytd)	-126.47M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Celldex Therapeutics Inc.

Trade With A Regulated Broker